Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study

Remdesivir is a drug widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during remdesivir therapy reaches 66%, with the most common is an increase in liver function tests.The aim of the work was to study the influence of clinica...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu. V. Shevchuk, A. V. Kryukov, I. I. Temirbulatov, I. V. Sychev, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, V. I. Vechorko, O. V. Averkov, D. A. Sychev
Format: Article
Language:Russian
Published: Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2023-11-01
Series:Фармация и фармакология (Пятигорск)
Subjects:
covid-19
remdesivir
hepatotoxicity
adverse reactions
predictors of adverse reactions
pharmacogenetic study
clinical trial
Online Access:https://www.pharmpharm.ru/jour/article/view/1355
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmpharm.ru/jour/article/view/1355

Similar Items